Phenobarbitone Idaman

Phenobarbitone Idaman

phenobarbital

Manufacturer:

Idaman Pharma

Distributor:

Pharmaniaga Logistics
Concise Prescribing Info
Contents
Phenobarb
Indications/Uses
Short-term treatment of insomnia; relieve anxiety, tension & apprehension; long-term anticonvulsant therapy for the treatment of generalised tonic clonic & simple partial seizures. Prophylaxis & treatment of febrile seizures. Prevention & treatment of hyperbilirubinemia in neonates.
Dosage/Direction for Use
Usual dose: 30-125 mg tds up to 350 mg daily in divided doses.
Contraindications
Hypersensitivity to barbiturates. Porphyria.
Special Precautions
Pregnancy & lactation. Childn. Elderly.
Adverse Reactions
Confusion, hallucinations, mental depression, skin rash or hives or swelling of eye lids, face or lips, wheezing or tightness in chest, sore throat & fever, unusual excitement & tiredness or weakness, yellowing of eyes & skin, clumsiness or unsteadiness, dizziness or lightheadedness, drowsiness, hangover's effect, anxiety or nervousness, constipation, feeling paint, headache, nausea, vomiting, nightmare or trouble in sleeping, unusual irritability.
Drug Interactions
Decreased effects of acetaminophen, adrenocorticoids, glucocorticoid & mineralocorticoid or corticotropin, cyclosporin, dacarbazine, digitalis glycosides, levothyroxine, quinidine, coumarin or indandione-derivative anticoagulants. Increased risk of habituation w/ other addictive drugs especially CNS depressants w/ habituating potential. Increased risk of hepatotoxicity w/ chronic use prior to enflurane, halothane or methoxyflurane anesth. Increased risk of nephrotoxicity prior to methoxyflurane anesth. Hydantoin anticonvulsants. Enhanced CNS depression w/ TCAs. Increased urinary excretion w/ ascorbic acid. Ca-channel blocking agents. Increased metabolism leading to decreased serum conc & reduced elimination t½ of carbamazepine. Carbonic anhydrase inhibitors. Increased CNS depression w/ other CNS depression-producing drugs. Estrogen-containing OCs, cyclophosphamide, disopyramide. Aggravated orthostatic hypotension w/ loop diuretics or guanadrel/guanethidine. Increased CNS depression & neurological toxicity w/ divalproex Na or valproic acid. Doxycycline. Decreased elimination t½ of fenoprofen. Decreased absorption of griseofulvin. Haloperidol. Increased risk of hypothermia w/ other hypothermia-producing drugs. Increased risk of hypotension &/or resp depression w/ ketamine. Leucovorin, loxapine, phenothiazines or thioxanthenes, maprotiline. Increased serum conc w/ methylphenidate. Accelerated metabolism & decreased plasma conc of mexiletine. Prolonged CNS depressant effects w/ MAOIs including furazolidone, pargyline & procarbazine. Increased risk of cardiac arrhythmias & coronary insufficiency w/ posterior pituitary. Primidone. Reduced effects w/ vit D. Xanthines eg, aminophylline, caffeine, oxtriphylline, theophylline.
MIMS Class
ATC Classification
N03AA02 - phenobarbital ; Belongs to the class of barbiturates and derivatives antiepileptics.
Presentation/Packing
Form
Phenobarbitone Idaman tab 30 mg
Packing/Price
1000's;10's;30's;500's;50's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in